179 related articles for article (PubMed ID: 32376737)
21. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
[TBL] [Abstract][Full Text] [Related]
23. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
25. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
26. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract][Full Text] [Related]
27. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair status in high-grade endometrial carcinomas of endometrioid and non-endometrioid type.
Doulgeraki T; Vagios S; Kavoura E; Yiannou P; Messini I; Nonni A; Papadimitriou C; Vlachos A; Pavlakis K
J BUON; 2019; 24(5):2020-2027. PubMed ID: 31786870
[TBL] [Abstract][Full Text] [Related]
29. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.
Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA
Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
32. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
[TBL] [Abstract][Full Text] [Related]
33. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
34. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
35. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI?
Ureyen I; Karalok A; Turkmen O; Kimyon G; Akdas YR; Akyol A; Tasci T; Turan T
Arch Gynecol Obstet; 2020 Mar; 301(3):737-744. PubMed ID: 31883046
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
[TBL] [Abstract][Full Text] [Related]
37. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
38. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
40. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes.
Bogani G; Tibiletti MG; Ricci MT; Carnevali I; Liberale V; Paolini B; Milione M; Vitellaro M; Murgia F; Chiappa V; Ditto A; Ghezzi F; Raspagliesi F
Int J Gynecol Cancer; 2020 Jan; 30(1):56-61. PubMed ID: 31780564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]